Loading clinical trials...
Loading clinical trials...
The main goal of this study is to employ a novel proteomic approach to identify predictive tumor biomarkers that will increase the efficacy of insulin-like growth factor (IGF1R) targeted therapy in epithelial ovarian cancer. It is expected that these predictive biomarkers will be applied to increase the response rate in selected groups of patients.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Hillel Yaffe Medical Center
Hadera, Israel
Start Date
April 1, 2016
Primary Completion Date
April 1, 2018
Completion Date
April 1, 2018
Last Updated
March 25, 2016
40
ESTIMATED participants
Immunohistochemistry staining method
OTHER
Lead Sponsor
Hillel Yaffe Medical Center
NCT04550494
NCT05039801
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions